

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

15 Jul 2026

### Investigation of Anti-inflammatory Effects of strowell capsules on Plasma Inflammatory Factors in Ischemic Stroke Patients: A Randomized, Double-blind Placebo-controlled Trial

#### Protocol summary

##### Study aim

Investigation of anti-inflammatory effect of strowell capsules on inflammatory factors in ischemic stroke patients

##### Design

Two arm parallel group randomized double-blind placebo-controlled trial

##### Settings and conduct

The trial is performed in Imam Hossein and Imam Khomeini Hospitals based on double-blind block randomization. All the people involved in the caregiving and treatment of the patients including companions, physicians, nurses and investigators are unbeknownst of the type of intervention.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: The inclusion age should be in 40-80 years range; National Institute of Health Stroke Scale (NIHSS) range is 4-20; and that of Body mass index (BMI) is 20-25. Focal neurological signs are confirmed by the Magnetic Resonance Imaging (MRI). Exclusion criteria: hemorrhagic stroke; history of Nonsteroidal Anti-inflammatory Drugs(NSAID) allergic response; history of gastrointestinal bleeding; kidney and liver failure; rheumatic and autoimmune diseases, myocardial infarction within previous 48 hours; previous stroke; pregnancy or lactation; malignancies; various other inflammatory diseases during the trial and those patients who have received tissue plasminogen activator (tPA).

##### Intervention groups

strowell capsules receiving group Placebo group

##### Main outcome variables

"Stroke intensity" "Blood Inflammatory markers"

#### General information

##### Reason for update

Due to publishing the results of the study under the

brand name Strowell, title has been modified accordingly.

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20170315033086N5**

Registration date: **2019-05-05, 1398/02/15**

Registration timing: **retrospective**

Last update: **2021-06-13, 1400/03/23**

Update count: **1**

##### Registration date

2019-05-05, 1398/02/15

##### Registrant information

##### Name

Saeed Karima

##### Name of organization / entity

Shahid Beheshti University of Medical Sciences (SBMU)

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 9666 1028

##### Email address

karima@sbmu.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2017-05-01, 1396/02/11

##### Expected recruitment end date

2018-08-02, 1397/05/11

##### Actual recruitment start date

2017-06-25, 1396/04/04

##### Actual recruitment end date

2018-12-01, 1397/09/10

##### Trial completion date

## Scientific title

Investigation of Anti-inflammatory Effects of strowell capsules on Plasma Inflammatory Factors in Ischemic Stroke Patients: A Randomized, Double-blind Placebo-controlled Trial

## Public title

Circulatory Cytokine Profiles of Ischemic Stroke Patients after Treatment with strowell capsules

## Purpose

Treatment

## Inclusion/Exclusion criteria

### Inclusion criteria:

Diagnosis, based on neurological diagnostic signs and confirmed by Magnetic Resonance Imaging (MRI)  
National Institutes of Health Stroke Scale (NIHSS) should be in 4 - 20 range at the time of admission. Body mass index (BMI) should be in 20-25 range No inflammatory diseases

### Exclusion criteria:

Hemorrhagic stroke transient ischemic attack (TIA)  
History of gastrointestinal bleeding History of sensitivity to NSIADs Previous stroke Myocardial infarction within the previous 48 hours Kidney and liver failure  
Immunosuppressive medications Stroke patients who have received tissue plasminogen activator (tPA).  
Rheumatoid and autoimmune diseases Malignancies  
Pregnancy or lactation

## Age

From **40 years** old to **80 years** old

## Gender

Both

## Phase

2

## Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

## Sample size

Target sample size: **80**

Actual sample size reached: **43**

## Randomization (investigator's opinion)

Randomized

## Randomization description

Randomization is designed based on four-sized block randomization procedure. A non-ordered computer sequence list including the patient-assigned code and the order of recruitment is generated by an epidemiologist. Given the block size of 4, there are 6 possible ways to equally assign participants to each treatment group. Therefore recruitment of participants to each treatment category is randomized and unpredictable. Following this randomization, an equal number of participants is randomly assigned to each treatment group.

## Blinding (investigator's opinion)

Double blinded

## Blinding description

Patient allocation and sequencing are done blindly. All the members of the staff who are involved in performing the enrollment, physicians, nurses and the investigation team as well as patients and their guardians, are masked. The research group is uninformed of drug and/or placebo prescription and its dosage. Codes will be written on the sealed envelopes and the medication bottles. Following patient assessment by the doctor, according to the admission sequence, the envelopes with the same number will be opened. Subsequently, the patients are going to be handed a bottle that could be the drug or placebo based on the assigned code. Therefore, the patient is unbeknownst whether the intervention is strowell capsules or the placebo.

## Placebo

Used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Shahid Beheshti University of Medical Sciences, School of Medicine

##### Street address

Ground floor, medical faculty, Koodakyar Alley, Daneshjoo Blvd, Velenjak, Tehran, Iran

##### City

Tehran

##### Province

Tehran

##### Postal code

1985717434

#### Approval date

2017-01-03, 1395/10/14

#### Ethics committee reference number

IR.SBMU.MSP.REC.1395.409

## Health conditions studied

### 1

#### Description of health condition studied

Ischemic stroke

#### ICD-10 code

I63.9

#### ICD-10 code description

Cerebral infarction, unspecified

## Primary outcomes

## 1

### Description

Stroke intensity

### Timepoint

At the commencement of the investigation and after taking the strowell capsules

### Method of measurement

NIH Stroke Scale questionnaire for quantifying stroke severity (11 items are included, level of consciousness, horizontal eye movement, visual field test, facial palsy, motor arm and motor leg, limb ataxia, sensory, language, speech, extinction and inattention)

## 2

### Description

Pro- and anti-inflammatory plasma markers

### Timepoint

At the investigation commencement and after the intervention

### Method of measurement

ELISA assay kit

## Secondary outcomes

empty

## Intervention groups

## 1

### Description

Intervention group: strowell capsules receiving group, 1 month, 3 times/day, Oral Administration (800 mg)

### Category

Treatment - Drugs

## 2

### Description

Control group: Placebo group, 1 month, 3 times/day, Oral (800 mg)

### Category

Treatment - Drugs

## Recruitment centers

## 1

### Recruitment center

#### Name of recruitment center

Imam Hossein Hospital

#### Full name of responsible person

Behnam Safarpour Lima

#### Street address

Shahid Madani St., Tehran, Iran

#### City

Tehran

#### Province

Tehran

#### Postal code

1617948615

#### Phone

+98 21 7343 3000

#### Email

info@ehmc.ir

## Sponsors / Funding sources

## 1

### Sponsor

#### Name of organization / entity

Shahid Beheshti University of Medical Sciences

#### Full name of responsible person

Behnam Safarpour Lima

#### Street address

Shahid Madani St., Tehran, Iran

#### City

Tehran

#### Province

Tehran

#### Postal code

1617948615

#### Phone

+98 21 7343 3000

#### Email

info@ehmc.ir

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Shahid Beheshti University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Private

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

Other

## Person responsible for general inquiries

### Contact

#### Name of organization / entity

Shahid Beheshti University of Medical Sciences

#### Full name of responsible person

Behnam Safarpour Lima

#### Position

Associate professor

#### Latest degree

Medical doctor

#### Other areas of specialty/work

Neurology

#### Street address

Shahid Madani St., Tehran, Iran

#### City

Tehran

**Province**  
Tehran  
**Postal code**  
1617948615  
**Phone**  
+98 21 7343 3000  
**Email**  
info@ehmc.ir

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**  
Shahid Beheshti University of Medical Sciences  
**Full name of responsible person**  
Behnam Safarpour Lima  
**Position**  
Associate professor  
**Latest degree**  
Medical doctor  
**Other areas of specialty/work**  
Neurology  
**Street address**  
Shahid Madani St., Tehran,  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1617948615  
**Phone**  
+98 21 7343 3000  
**Email**  
info@ehmc.ir

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Shahid Beheshti University of Medical Sciences  
**Full name of responsible person**  
Behnam Safarpour Lima  
**Position**  
Associate professor  
**Latest degree**  
Medical doctor  
**Other areas of specialty/work**  
Neurology  
**Street address**

Shahid Madani St., Tehran  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1617948615  
**Phone**  
+98 21 7343 3000  
**Email**  
info@ehmc.ir

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

### Study Protocol

Yes - There is a plan to make this available

### Statistical Analysis Plan

Yes - There is a plan to make this available

### Informed Consent Form

Yes - There is a plan to make this available

### Clinical Study Report

Not applicable

### Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

### Data Dictionary

Not applicable

### Title and more details about the data/document

collected de-identified IPD, IPD collected for the primary outcome measure only

### When the data will become available and for how long

De-identified data will be available starting from April, 2021

### To whom data/document is available

Academics employed at various research/university institutions and the industry.

### Under which criteria data/document could be used

No specific condition are specified.

### From where data/document is obtainable

Behnam Safarpour Lima, Shahid Madani St., Tehran, Iran, Tel: +982173433000 Mob. 091229811576

### What processes are involved for a request to access data/document

1- The applicant would be asked to provide a written formal request letter, containing the importance of the data and the project processes. 2- Following the receipt of request letter, the data would be provided in no more than two weeks.

### Comments